Amendments

In the Specification:

Please substitute the following paragraphs for the pending paragraphs:

Substitute the paragraph beginning on page 3, line 1, with the following paragraph:

E1

Variations in subunit combinations can result in different pharmacological properties being conferred upon the receptor complex (Davies, P.A. *et al., Nature 385*:820-823 (1997); reviewed in Whiting, P.J. *et al., Int. Rev. Neurobiol. 38*:95-138 (1995)). Thus, subpopulations of $GABA_A$ receptor complexes show differing sensitivity to GABA, steroid modulators, physiological regulation, disease processes, and pharmacological manipulation by drugs (*e.g.*, benzodiazepines). The distributions of mRNAs encoding different $GABA_A$ receptor subunit polypeptides and their subtypes localized in the brain show significant regional variation consistent with pharmacological and biochemical evidence for receptor heterogeneity. Further, alterations in brain specific expression of $GABA_A$ receptor complex subunit polypeptides have been identified in human brain tissues of individuals suffering from alcoholism (Lewohl, J. *et al., Brain Res. 751*:102-112 (1997)).

Substitute the paragraph beginning on page 6, line 3, with the following paragraph:

E2

The invention further provides isolated polypeptides having an amino acid sequence selected from the group consisting of: (a) the amino acid sequence of the ET2 polypeptide having the complete 242 amino acid sequence; (b) the amino acid sequence of the GABRE polypeptide having the complete 506 amino acid sequence; (c) the amino acid sequence of the ET2 polypeptide having the complete 242 amino acid sequence but minus the N-terminal methionine residue; (d) the amino acid sequence of the GABRE polypeptide having the complete 506 amino acid sequence but minus the N-terminal methionine residue; (e) the amino acid sequence of the mature GABRE protein; (f) the amino acid sequence of one or more ET2 or GABRE transmembrane domains; (g) the amino acid sequence of the ET2 or

E2 Cont

GABRE intracellular domain; (h) the amino acid sequence of the GABRE extracellular domain; and (i) the amino acid sequence of the ET2 or GABRE protein with all or part of one or more of the transmembrane domains deleted.

Substitute the paragraph beginning on page 16, line 1, with the following paragraph:

E3

In another aspect, the invention provides isolated nucleic acid molecules encoding the GABRE polypeptide having an amino acid sequence as encoded by the cDNA clone contained in the plasmid deposited as ATCC Deposit No. 209642 on February 25, 1998. In a further aspect, nucleic acid molecules are provided encoding the full-length ET2 or GABRE polypeptide lacking the N-terminal methionine. The invention also provides an isolated nucleic acid molecule having the nucleotide sequence shown in SEQ ID NO:1 or SEQ ID NO:41, or a nucleic acid molecule having a sequence complementary to that of SEQ ID NO:1 or SEQ ID NO:41. Such isolated molecules, particularly DNA molecules, are useful as probes for gene mapping, for *in situ* hybridization with chromosomes, and for detecting expression of ET2 or GABRE nucleotide sequences in human tissue, for instance, by Northern blot analysis.

Substitute the paragraph beginning on page 18, line 16, with the following paragraph:

E4

In another aspect, the invention provides isolated nucleic acid molecules comprising polynucleotides which hybridize under stringent hybridization conditions to a portion of the polynucleotide in a nucleic acid molecule of the invention described above, for instance, the cDNA sequences shown in SEQ ID NO:1 and SEQ ID NO:41, or the cDNA clone contained in ATCC Deposit No. 209642. By "stringent hybridization conditions" is intended overnight incubation at 42°C in a solution comprising: 50% formamide, 5x SSC (750 mM NaCl, 75mM trisodium citrate), 50 mM sodium phosphate (pH 7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 μg/ml denatured, sheared salmon sperm DNA, followed by washing the filters in 0.1x SSC at about 65°C.